FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial
FOLFIRI联合度伐利尤单抗（加或不加曲美利木单抗）二线治疗晚期胃癌或胃食管交界处腺癌：PRODIGE 59-FFCD 1707-DURIGAST随机临床试验
期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2024.0207
Tougeron, David; Dahan, Laetitia; Evesque, Ludovic; Le Malicot, Karine; El Hajbi, Farid; Aparicio, Thomas; Bouché, Olivier; Bonichon Lamichhane, Nathalie; Chibaudel, Benoist; Angelergues, Antoine; Bodere, Anaïs; Phelip, Jean-Marc; Mabro, May; Kaluzinski, Laure; Petorin, Caroline; Breysacher, Gilles; Rinaldi, Yves; Zaanan, Aziz; Smith, Denis; Gouttebel, Marie-Claude; Perret, Clément; Etchepare, Nicolas; Emile, Jean-François; Sanfourche, Ivan; Di Fiore, Frédéric; Lepage, Côme; Artru, Pascal; Louvet, Christophe
